Predicting Mouse Liver Microsomal Stability with “Pruned” Machine Learning Models and Public Data
暂无分享,去创建一个
[1] Sean Ekins,et al. Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis. , 2010, Molecular bioSystems.
[2] Sean Ekins,et al. Novel diaryl ureas with efficacy in a mouse model of malaria. , 2013, Bioorganic & medicinal chemistry letters.
[3] Sean Ekins,et al. Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties , 2010, Drug Metabolism and Disposition.
[4] Franco Lombardo,et al. A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. , 2006, Journal of medicinal chemistry.
[5] O. Sansom,et al. MYC‐y mice: From tumour initiation to therapeutic targeting of endogenous MYC , 2013, Molecular oncology.
[6] Søren Balling Engelsen,et al. Prediction of in vitro metabolic stability of calcitriol analogs by QSAR , 2003, J. Comput. Aided Mol. Des..
[7] Sean Ekins,et al. Fusing Dual-Event Data Sets for Mycobacterium tuberculosis Machine Learning Models and Their Evaluation , 2013, J. Chem. Inf. Model..
[8] D. Lewis,et al. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. , 2000, Biochemical pharmacology.
[9] Sean Ekins,et al. Computational Prediction and Validation of an Expert's Evaluation of Chemical Probes , 2014, J. Chem. Inf. Model..
[10] Sean Ekins,et al. Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. , 2009, Drug discovery today.
[11] Sean Ekins,et al. Progress in computational toxicology. , 2014, Journal of pharmacological and toxicological methods.
[12] D. Rogers,et al. Using Extended-Connectivity Fingerprints with Laplacian-Modified Bayesian Analysis in High-Throughput Screening Follow-Up , 2005, Journal of biomolecular screening.
[13] M. Molloy,et al. From mice to men: GEMMs as trial patients for new NSCLC therapies. , 2014, Seminars in cell & developmental biology.
[14] E. Gifford,et al. The development and validation of a computational model to predict rat liver microsomal clearance. , 2009, Journal of pharmaceutical sciences.
[15] Sean Ekins,et al. A Predictive Ligand-Based Bayesian Model for Human Drug-Induced Liver Injury , 2010, Drug Metabolism and Disposition.
[16] C. Hansch,et al. The QSAR paradigm in the design of less toxic molecules. , 1984, Drug metabolism reviews.
[17] D. Lewis,et al. Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1). , 1997, Drug metabolism reviews.
[18] Sean Ekins,et al. Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). , 2013, Molecular pharmaceutics.
[19] C. Pipper,et al. [''R"--project for statistical computing]. , 2008, Ugeskrift for laeger.
[20] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[21] Franco Lombardo,et al. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. , 2002, Journal of medicinal chemistry.
[22] Sean Ekins,et al. Validating New Tuberculosis Computational Models with Public Whole Cell Screening Aerobic Activity Datasets , 2011, Pharmaceutical Research.
[23] Anthony E. Klon,et al. Improved Naïve Bayesian Modeling of Numerical Data for Absorption, Distribution, Metabolism and Excretion (ADME) Property Prediction , 2006, J. Chem. Inf. Model..
[24] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[25] Michele Connelly,et al. Repositioning: the fast track to new anti-malarial medicines? , 2014, Malaria Journal.
[26] Sean Ekins,et al. A collaborative database and computational models for tuberculosis drug discovery. , 2010, Molecular bioSystems.
[27] M. Bentires-Alj,et al. Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors , 2013, The FEBS journal.
[28] Maurice Dickins,et al. Compound lipophilicity for substrate binding to human P450s in drug metabolism. , 2004, Drug discovery today.
[29] Sean Ekins,et al. Enhancing Hit Identification in Mycobacterium tuberculosis Drug Discovery Using Validated Dual-Event Bayesian Models , 2013, PloS one.
[30] A. Tropsha,et al. Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. , 2003, Journal of medicinal chemistry.
[31] Li Di,et al. Development of QSAR models for microsomal stability: identification of good and bad structural features for rat, human and mouse microsomal stability , 2010, J. Comput. Aided Mol. Des..
[32] K. Korzekwa,et al. Predicting the rates and regioselectivity of reactions mediated by the P450 superfamily. , 1996, Methods in enzymology.
[33] Sean Ekins,et al. Computational models for tuberculosis drug discovery. , 2013, Methods in molecular biology.
[34] Jing Lu,et al. Development of in silico models for human liver microsomal stability , 2007, J. Comput. Aided Mol. Des..
[35] M H Tarbit,et al. Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. , 1998, Chemico-biological interactions.
[36] Sean Ekins,et al. Are Bigger Data Sets Better for Machine Learning? Fusing Single-Point and Dual-Event Dose Response Data for Mycobacterium tuberculosis , 2014, J. Chem. Inf. Model..
[37] M. Vignali,et al. Of men in mice: the success and promise of humanized mouse models for human malaria parasite infections , 2014, Cellular microbiology.
[38] Alex M. Clark,et al. Open Source Bayesian Models. 2. Mining a "Big Dataset" To Create and Validate Models with ChEMBL , 2015, J. Chem. Inf. Model..
[39] Sandhya Kortagere,et al. In Silico Models for Drug Discovery , 2013, Methods in Molecular Biology.
[40] Arthur J. Olson,et al. A Virtual Screen Discovers Novel, Fragment-Sized Inhibitors of Mycobacterium tuberculosis InhA , 2015, J. Chem. Inf. Model..
[41] F. Sanz,et al. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. , 1993, Molecular pharmacology.
[42] C. Hansch. Quantitative Relationships Between Lipophilic Character and Drug Metabolism , 1972 .
[43] R. Tekmal,et al. Transgenic mouse models of hormonal mammary carcinogenesis: Advantages and limitations , 2012, The Journal of Steroid Biochemistry and Molecular Biology.
[44] D. Winkler,et al. Rapid prediction of chemical metabolism by human UDP-glucuronosyltransferase isoforms using quantum chemical descriptors derived with the electronegativity equalization method. , 2004, Journal of medicinal chemistry.
[45] K. Befort,et al. 15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse , 2014, Neuropharmacology.
[46] Barry A. Bunin,et al. Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery. , 2013, Chemistry & biology.
[47] A. Rosato,et al. In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes. , 2008, Biochemical pharmacology.
[48] Alex M. Clark,et al. New target prediction and visualization tools incorporating open source molecular fingerprints for TB Mobile 2.0 , 2014, Journal of Cheminformatics.
[49] Yanli Wang,et al. PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..
[50] Jeffrey P. Jones,et al. Predicting intrinsic clearance for drugs and drug candidates metabolized by aldehyde oxidase. , 2013, Molecular pharmaceutics.
[51] Alex M. Clark,et al. Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets , 2015, J. Chem. Inf. Model..
[52] Sean Ekins,et al. Combining Computational Methods for Hit to Lead Optimization in Mycobacterium Tuberculosis Drug Discovery , 2013, Pharmaceutical Research.
[53] W. Denny,et al. Synthesis and Structure−Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824) , 2010 .
[54] V. Dartois,et al. A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. , 2013, Bioorganic & medicinal chemistry letters.
[55] M. Wunderlich,et al. Xenograft models for normal and malignant stem cells. , 2015, Blood.
[56] D. Lewis,et al. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. , 2000, Toxicology.
[57] Sean Ekins,et al. Novel Applications of Kernel–Partial Least Squares to Modeling a Comprehensive Array of Properties for Drug Discovery , 2006 .
[58] Sean Ekins,et al. Methods for predicting human drug metabolism. , 2007, Advances in clinical chemistry.
[59] Xiaoyang Xia,et al. Classification of kinase inhibitors using a Bayesian model. , 2004, Journal of medicinal chemistry.
[60] Antony J. Williams,et al. Looking Back to the Future: Predicting in Vivo Efficacy of Small Molecules versus Mycobacterium tuberculosis , 2014, J. Chem. Inf. Model..
[61] Sean Ekins,et al. Computational Approaches That Predict Metabolic Intermediate Complex Formation with CYP3A4 (+b5) , 2007, Drug Metabolism and Disposition.
[62] Franco Lombardo,et al. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. , 2004, Journal of medicinal chemistry.
[63] C. Locuson,et al. THREE-DIMENSIONAL QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS OF CYTOCHROMES P450: EFFECT OF INCORPORATING HIGHER-AFFINITY LIGANDS AND POTENTIAL NEW APPLICATIONS , 2005, Drug Metabolism and Disposition.
[64] Christopher P Austin,et al. Monitoring Compound Integrity With Cytochrome P450 Assays and qHTS , 2009, Journal of biomolecular screening.
[65] I. Campbell,et al. Chronic Neuroinflammation in Alzheimer's Disease: New Perspectives on Animal Models and Promising Candidate Drugs , 2014, BioMed research international.
[66] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[67] Sean Ekins,et al. In silico repositioning of approved drugs for rare and neglected diseases. , 2011, Drug discovery today.
[68] Lars Carlsson,et al. State-of-the-art Tools for Computational Site of Metabolism Predictions: Comparative Analysis, Mechanistical Insights, and Future Applications , 2007, Drug metabolism reviews.
[69] D. Huryn,et al. Optimization of a Higher Throughput Microsomal Stability Screening Assay for Profiling Drug Discovery Candidates , 2003, Journal of biomolecular screening.
[70] Ruili Huang,et al. Predictive Models for Cytochrome P450 Isozymes Based on Quantitative High Throughput Screening Data , 2011, J. Chem. Inf. Model..
[71] S. Ekins. In silico approaches to predicting drug metabolism, toxicology and beyond. , 2003, Biochemical Society transactions.
[72] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[73] T. Dick,et al. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. , 2015, The Journal of antimicrobial chemotherapy.
[74] Evan Bolton,et al. PubChem's BioAssay Database , 2011, Nucleic Acids Res..
[75] Barry C. Jones,et al. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.
[76] C. Hansch,et al. Quantitative structure-activity relationships of cytochrome P-450. , 1993, Drug metabolism reviews.
[77] Ruili Huang,et al. Comprehensive Characterization of Cytochrome P450 Isozyme Selectivity across Chemical Libraries , 2009, Nature Biotechnology.
[78] Ruili Huang,et al. Prediction of Cytochrome P450 Profiles of Environmental Chemicals with QSAR Models Built from Drug‐Like Molecules , 2012, Molecular informatics.
[79] A. Hersey,et al. X-ray Crystal Structure of Human Dopamine Sulfotransferase, SULT1A3 , 1999, The Journal of Biological Chemistry.
[80] F. Lombardo,et al. ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. , 2001, Journal of medicinal chemistry.
[81] Philip Prathipati,et al. Global Bayesian Models for the Prioritization of Antitubercular Agents , 2008, J. Chem. Inf. Model..
[82] David Rogers,et al. Cheminformatics analysis and learning in a data pipelining environment , 2006, Molecular Diversity.
[83] L. Isaacs,et al. New Small-Molecule Inhibitors Effectively Blocking Picornavirus Replication , 2014, Journal of Virology.
[84] Joel S. Freundlich,et al. Minding the gaps in tuberculosis research. , 2014, Drug discovery today.
[85] John P. Overington,et al. The ChEMBL database: a taster for medicinal chemists. , 2014, Future medicinal chemistry.
[86] W. Denny,et al. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). , 2010, Journal of medicinal chemistry.
[87] R. Mendes. R: The R Project for Statistical Computing , 2016 .
[88] C. Hansch,et al. Structure--activity correlations in the metabolism of drugs. , 1968, Archives of biochemistry and biophysics.
[89] Robert Richbourg,et al. Modeling the Environment , 2015 .
[90] Sarah R. Langdon,et al. Predicting cytotoxicity from heterogeneous data sources with Bayesian learning , 2010, J. Cheminformatics.
[91] D. Rigal,et al. Les souris ne sont pas des hommes et pourtant… : Ce que les souris humanisées nous apprennent sur les maladies infectieuses , 2012 .
[92] Chris Oostenbrink,et al. Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450. , 2008, Expert opinion on drug metabolism & toxicology.
[93] I. Orme,et al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. , 2012, Tuberculosis.
[94] I. Poggesi,et al. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. , 2006, European journal of medicinal chemistry.